AptarGroup has beaten earnings four quarters in a row and carries solid quality (Piotroski 8/9) with strong momentum, but the price is within 2.9% of the analyst target and growth is weak, so reward-to-risk is only 0.21.
Thesis pillars
- Perfect Earnings Beat Streak↓Deteriorating
- Limited Upside To Target↓Deteriorating
- Solid Financial Quality↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Feb 6, 2026
AptarGroup, Inc. (ATR) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. Analyst target reached at $146.86 — A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single-source resins and rubber components.
AptarGroup designs and manufactures drug and consumer product dosing, dispensing, and protection technologies through three segments: Pharma (46% of net sales), Beauty (35%), and Closures (19%), serving approximately 5,000 customers globally. Europe represents 49% of 2025... Read more
Sell if holding. Analyst target reached at $146.86 — A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single-source resins and rubber components. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 91d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About AptarGroup, Inc.
About AptarGroup, Inc.
AptarGroup's Pharma segment — the largest by revenue at 46% of net sales and 69% of adjusted EBITDA — supplies nasal drug delivery pumps, metered dose inhaler valves, and elastomeric injectable packaging components to pharmaceutical customers worldwide, with clean-room manufacturing in Argentina, China, France, Germany, India, Switzerland, and the United States. Beauty contributed 35% of net sales and Closures 19%. Europe accounted for 49% of 2025 consolidated sales by ship-to location, with Asia and Latin America combined adding another approximately 20%.
Aptar earns revenue by co-developing proprietary dispensing systems with pharmaceutical and consumer goods customers through lengthy regulatory and commercial qualification timelines. In the Pharma segment, nasal allergy pumps and MDI valves for respiratory conditions such as asthma and COPD anchor recurring volume; injectables — stoppers, plungers, and pre-filled syringe components for GLP-1 biologics and vaccines — accounted for approximately 19% of Pharma net sales in 2025. Sales to prescription drug and digital health markets were approximately 51% of Pharma net sales. Certain resins and rubber components for the Pharma segment are sourced from a single supplier, so a supply disruption could impair near-term delivery before alternative source qualification is completed. In Closures, food applications (49% of segment sales) and beverage (26%) dominate, with sustainability features such as post-consumer recycled resin and tethered closures driving incremental design wins.
Show full overview
AptarGroup's pharmaceutical customer relationships embed a regulatory binary: the company invests years co-developing drug delivery devices alongside a customer's clinical program, and if the FDA or a comparable regulator rejects the customer's drug, the development investment may not generate a future return. Two active litigation matters sharpen this risk profile. In May 2025, Nemera filed patent infringement actions in France and Germany relating to certain ophthalmic products; an EPO hearing in October 2025 invalidated Nemera's main patent claim while allowing an amended claim to continue. Separately, ARS Pharmaceuticals filed a U.S. antitrust lawsuit in September 2025 in the Southern District of California relating to supply of certain components, seeking injunctive relief and damages.
See also: Healthcare · Medical Instruments & Supplies
From AptarGroup, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated Oct 29, 2026Recent Developments — AptarGroup, Inc.
Latest news
- NEWS AptarGroup (ATR) Reports Q3 Revenue Beat, Reinforces Growth Stra - GuruFocus — GuruFocus Oct 29, 2026 positive
- NEWS AptarGroup (ATR) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance — Yahoo Finance Oct 29, 2026 positive
- NEWS AptarGroup (ATR) Releases Q3 2026 Earnings: Revenue Growth but EPS Miss - Quiver Quantitative — Quiver Quantitative Oct 29, 2026 negative
- NEWS AptarGroup Q3 Adjusted Earnings Fall, Sales Rise - Yahoo Finance — Yahoo Finance Oct 29, 2026 negative
- NEWS AptarGroup (NYSE:ATR) Stock Price Breaks Above 200-Day Moving Average - Here's Why - MarketBeat — MarketBeat Oct 27, 2026 positive
Latest item Oct 29, 2026 · Generated 2026-11-05T11:59:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicEurope49%10-K Item 1: 'Europe is our largest region in terms of sales ... were approximately 49% and 49% of our consolidated sales, respectively.'
- HIGHSuppliersingle-source resins and rubber components10-K Item 1A: 'we have historically sourced certain materials, especially some resins and rubber components for our Pharma segment, from a single source.'
Material Events(8-K, last 90d)
- 2026-05-13Item 5.02LOWAditya Gandhi appointed VP and Chief Accounting Officer effective June 8, 2026, succeeding Daniel Ackerman who moved to another leadership role within Aptar Finance. No disagreement cited.SEC filing →
- 2026-03-17Item 5.02MEDIUMCEO Stephan Tanda to retire September 1, 2026. Gael Touya, President of Aptar Pharma segment since 2018, appointed as successor CEO and expected to join the Board on the same effective date.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $146.86 — A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single-source resins and rubber components. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $139.70. Score 5.0/10, moderate confidence.
Analyst target $142.57 reached (−2.9% from $146.86); no take-profit level is published. Prior stop was $139.70. Stop-loss: $139.70.
Concentration risk — Supplier: single-source resins and rubber components; Analyst target reached - limited upside remaining; Near 52-week high (0.2% away).
AptarGroup, Inc. trades at a P/E of 35.5 (forward 23.7). TrendMatrix value score: 4.8/10. Verdict: Sell.
14 analysts rate ATR, with a consensus score of 4.1/5. 8 analysts publish price targets averaging $164.
What does AptarGroup, Inc. do?AptarGroup designs and manufactures drug and consumer product dosing, dispensing, and protection technologies through...
AptarGroup designs and manufactures drug and consumer product dosing, dispensing, and protection technologies through three segments: Pharma (46% of net sales), Beauty (35%), and Closures (19%), serving approximately 5,000 customers globally. Europe represents 49% of 2025 consolidated sales, with no single customer exceeding 4% of net sales and approximately 14,000 employees across about 20 countries.